2. Barnett MJ, Richards MA, Ganesan TS, et al. Central nervous system toxicity of high- dose cytosine arabinoside. Semin Oncol. Jun;12(2 Suppl 3):227-32 (1985)

BIBLIOGRAFIA

1. Avramis VI, Biener R, Krailo M, et al. Biochemical pharmacology of high dose 1- beta-D-arabinofuranosylcytosine in childhood acute leukemia. Cancer Res. Dec;47(24 Pt 1):6786-92 (1987)

2. Barnett MJ, Richards MA, Ganesan TS, et al. Central nervous system toxicity of high- dose cytosine arabinoside. Semin Oncol. Jun;12(2 Suppl 3):227-32 (1985)

3. Bergaman AM, Ruiz Van Haperen VW, Smind K, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleoside reductase subunit M1 as the major determinant. Cancer Res. Oct 15;65(20):9510-6 (2005)

4. Betts L, Xiang S, Short SA, et al. Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex. J Mol Biol. Jan 14;235(2):635-56 (1994) 5. Cacciamani T, Vita A, Cristalli G. et al. Purification of human cytidine deaminase : molecular and enzymatic characterization and inhibition by sysnthetic pyrimidine analogs. Arch Biochem Biophys. Nov 1;290(2):285-92 (1991)

6. Capizzi RL, Yang JL, Cheng E et al. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J.Clin Oncol.

Dec;1(12):763-71 (1983)

7. Capizzi RL, Yang JL, Rathmell JP et al. Dose-related pharmacologic effects of High doe ara-C and its self-potentiation. Semin Oncol. Life Sci. Jul 2;25(1):1-14 (1979) 8. Chabner BA, Hande KR, Drake JC et al. Ara-C metabolism: implication for drug resistance abd drug interactions. Bull. Cancer Jul 2;25(1):1-14 (1979 )

9. Chiba P, Thihan T, Szekeres T et al. Concordant changes of pyrimidine metabolism in blasts ot two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo. Leukemia. Nov;4(11):761-5 (1990)

10. Choi DS, Hnda M, Yuong H, et al. Genomic orgazation and expression of the mouse equilibrative, nitrobenzylthioinosine- sensitive nucleoside transporter 1 (ENT1) gene.

Biochem Biophys Oct 14;277(1):200-8 (2000)

11. Chou TC, Arlin Z, Clarkson BD et al: Metabolism of 1-β-D-

arabinofuranosylcytosine in human leukemic cells. Cancer Res. Oct;37(10):3561-70 (1977)

12. Clarke ML, Mackey JR, Baldwin SA et al. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res. Oct;112:27-47 (2002)

13. Creutzig U, Berthold F, Boss J et al. Treatment with all-trans retinoic acid in acute

promyelocytic leukemia reduces early deaths in children. Klin Padiatr Jan;. 213, 175-

185 (2001).

14. Damaraju VL, Damaraju S, Yuong JD, et al. The role of clofarabine in hematologic and solid malignancies-development of a next- generation nucleoside analog. Mol Pharmacol. Jan;69(1):346-53.(2006)

15. Galmarini CM, Mackey JR, Dumontet C et al. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Haematologica. Dec;90(12):1699-701.(2005) 16. Galmarini CM, Thomas X, Calvo F et al. In vivo mechanisms of resistance to

cytarabine in acute myeloid leukemia. Lancet Oncol. Jul;3(7):415-24 (2002)

17. Gandhi V, Plunkett W, Cell cycle-specific Metabolism of arabinosyl nucleosides in K562 Human leukemia cells. Cancer Chemother Pharmacol. Jan;31(1):11-7 (2002) 18. Gandhi V, Wiersma S, Krailo MD et al.: Biochemical modulation of

arabinosylecytosine for therapy of leukemia. Leuk Lymphoma. Oct;10 Suppl:109-14 (2003)

19. Gilbert JA, Salvaggione OE, Ji Y et al: Gemcitabine pharmacogenomics: cytadine deaminase and deoxycytidylate deaminase gene resquencing and functional genomics.

Clin Cancer Res. Mar; 15;12(6):1794-803 (2006)

20. Giovannetti E, Mey V, Lioni L et al: Cytotoxic activity of gemcitabine and

correlation with expression profile of drug-related genes in human lymphoid cells.

Pharmacol Res. Apr;55(4):343-9 (2007)

21. Grant, S: Ara-C : cellular and molecular pharmacology. Mol Pharmacol.

Nov;54(5):844-56 (1998)

22. Hapke DM, Stegmann AP, Mitchell BS et al . Retroviral transfer of deoxycytidine kinasem into tumor cell lines enchancer nucleoside Toxicity. Cancer Res. May 15;56(10):2343-7 (1996)

23. Harris Re, Methotrexate-L-Asparaginase combination chemotherapy for patient with acute leukemia in relapse: a study of 36 children. Cancer. Nov 1;46(9):2004-8 (1990)

24. Hirsh MS, Tresimen of Herpcs Virus Infections”. Clin Invest. Sep;25(5):665-72 (1982)

25. Hyde RJ, Cass CE, Yuong JD et al. The ENT family of eukaryote nucleoside and nucleobase transportes: recent advance in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membr Biol. Jan- Mar;18(1):53-6 (2001)

26. Jahns-Streubel G, Retuter C, Auf der Landwehr U et al. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine

deaminase in leukemic blasts are correlated with clinical response in the setting of

granulocyte-macrophage colony-stimulating factor-based priming before and during

TAD-9 induction therapy in acute myeloid leukemia. Clin Lab. Mar; 53(3-4):211-5

(1976)

27. Kim SO, Jeong JY, Kim MR et al.: Efficacy of gemcitabine in patients with non small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin. Clin Cancer Res. May;15;14(10):3083-8 (2008)

28. Kroep JR, Giaccone G, Tolis C, et al. Sequence dependent effects of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell.lines. Br J Cancer. Oct;83(8):1069-76 (2000)

29. Kufe DW, Major PP, Engan EM et al. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem. Oct; 10;255(19):8997-900 (1980)

30. Kufe DW, Munroe D, Herrick D et al. Effects of 1-β-D- arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol Pharmacolm 4

Jul;26(1):128-34 (1980)

31. Major PP, Egan EM, Beardsley GP, et al. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci U S A.

May;78(5):3235-9 (1981)

32. Mompaler RL, Fischer GA: Mammalian Deoxynucleoside kinase. I. Deoxycytidine

kinase: purification, properties and kinetic studies with cytosine arabinoside. Conn

Med. Dec;31(12):880 (1968)

33. Momparler RL, Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells..

Cancer Gene Ther. Sep-Oct;3(5):331-8 (1996)

34. Muller WE, Metabolism of 1-beta-D-arabinofuranosyluracile in mouse L5178Y cells. Chemotherapy. ;27(1):53-60 (1981)

35. Osato dh, Huang CC, Kawamoto M et al. Fuctional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1.

Pharmacogenetics. May;13(5):297-301 (2003)

36. Osato DH, Huang CC, Kawamoto M et al. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporte, ENT1.

Pharmacogenetics. May;13(5):297-301 (2003)

37. Plunkett W, Iacobini S, Estey E et al. pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol. Jun;12(2 Suppl 3):20-30 (1985)

38. Ramzi S., Vinay K, Tucker C. et al. Le basi patologiche delle malattie Robbins (2000).

39. Riva C.M, Pharmacokinetics and cellular determinants of response to 1-β- arabinofuranosylcitosine(ara-C). Semin Oncol Jun;12(2 Suppl 3):1. (1985)

40. Schroder JK, Kirch C, Flasshove M et al. Constititive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Semin Oncol.

Jun;12(2 Suppl 3):20-30 (1985)

41. Schroder JK, Kirch C, Seeber S et al. Structural and functional analysis of the cytidine deaminasi gene in patients with acute myeloid leukemia. Br J Haematol.

Dec;103(4):1096-103 (1998)

42. Sigmond J, Kamphuis JA, Laan AC et al. The synergistic interation of gemcitabina cytosine arabinoside with ribonucleotide reductase inhibitor triapine in schedule dependent. Biochem Pharmacol. May; 15;73(10):1548-57. Epub 2007 Jan 21 (2007) 43. Stegmann AP, Honders WH, Willenmze R, et al. Transfection of wylde type

deoxycytide kinase ( DCK) c DNA into an ara-C and DAC-resistant rat leukemia cell line of clonal origin fully restores drug sensitivity. Blood. Mar;1;85(5):1188-94 (1995) 44. Sundaram M, Yao SY, Ingram JC et al. Topology of a human equilibrative,

nitrobenzylthioinosine (NBMPR)-semsitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. J Biol Chem. Nov;

30;276(48):45270-5. Epub ( 2001)

45. Wang JJ, Selawry OS, Vietti TL et al. Prolonged infusion of arabinosyl cytosine in childhood leukemia. Cancer. Jan;25(1):1-6 (1970)

46. Weick Jk, Kopecky KJ, Appelbaum FR et al. a randomized investigation nof hight- dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.

Blood. Oct;15;88(8):2841-51 (1996)

47. Wiley J.S, cytosine arabinoside influx and nucleoside tran sport sites inacute leukemia. J Clin Invest. Feb;69(2):479-89 (1982)

48. Wiley JS, Jones SOP, Sawyer WH et al. Cytosine arabinoside transport by human leukemic cells. Eur J Cancer Clin Oncol. Aug;19(8):1067-74 (1983)

49. Wiley JS, Taupin J, Jamieson GP et al. Cytosine arabinoside transport and

metabolism in acute leukemias and T celllymphoblastic lymphoma. Eur J Cancer Clin Oncol. Sep;21(9):1077-82 (1985)

50. Woodruff R. K., Wiley J.S. Hight dose cytosine arabinoside: advances in clinical pharmacology and therapeutic results. Aust N Z J Med. Dec;13(6):561-3 (1983) 51. Yue L, Saikawa Y, Ota et al. A functional single-nucleotide polymorphism in the human cytidine deaminasi gene contributing to ara-C sensitivity. Pharmacogenetics.

Jan;13(1):29-38 (2003)